Aurion Biotech

Greg Kunst, CEO 

April 11 | 11:30am | Salone dei Cavalieri, Section 2

Seattle, WA 


Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech is the recipient of the prestigious Prix Galien award for Best Start-Up in Biotech. The Company’s first candidate, AURN001, is an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial disease. It is the first off-the-shelf, clinically validated cell therapy for corneal care, having received regulatory approval in Japan. The Company has initiated clinical trials in the U.S. in 2023. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions